Westfield Capital Management Co. LP Purchases Shares of 137,936 Pfizer Inc. $PFE

Westfield Capital Management Co. LP acquired a new position in shares of Pfizer Inc. (NYSE:PFE) in the 4th quarter, HoldingsChannel.com reports. The institutional investor acquired 137,936 shares of the biopharmaceutical company’s stock, valued at approximately $3,435,000.

Other large investors also recently modified their holdings of the company. Horizon Financial Services LLC increased its position in shares of Pfizer by 174.8% during the fourth quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 645 shares during the period. Godfrey Financial Associates Inc. acquired a new stake in shares of Pfizer during the fourth quarter worth $26,000. YANKCOM Partnership acquired a new stake in shares of Pfizer during the fourth quarter worth $28,000. HFM Investment Advisors LLC increased its position in shares of Pfizer by 61.0% during the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 427 shares during the period. Finally, Darwin Wealth Management LLC acquired a new stake in shares of Pfizer during the second quarter worth $32,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on PFE shares. Citigroup increased their price objective on shares of Pfizer from $26.00 to $27.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 29th. Daiwa Securities Group cut shares of Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 price objective for the company. in a research report on Thursday, February 12th. Argus upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $35.00 price objective for the company in a research report on Monday, March 2nd. Guggenheim increased their price objective on shares of Pfizer from $35.00 to $36.00 and gave the stock a “buy” rating in a research report on Tuesday, March 24th. Finally, Zacks Research upgraded shares of Pfizer from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 24th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, eleven have given a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $28.82.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer signed a license agreement with Chai Discovery to gain early access to its AI drug-discovery platform, including the new Chai-3 model, which could improve antibody design and speed up research productivity. Pfizer signs licence agreement with Chai for AI drug discovery
• Positive Sentiment: Pfizer also reported fresh clinical-trial progress across its oncology pipeline, including updates on a lung cancer study, a bladder cancer combination trial with Astellas, and another advanced lung cancer combination program, signaling continued investment in future growth drivers. Pfizer’s New Lung Cancer Study Signals Fresh Oncology Upside for PFE Investors
• Positive Sentiment: Pfizer disclosed an update on a Phase 3 infant pneumococcal vaccine trial, suggesting continued momentum in its vaccine franchise and potential additional data catalysts ahead. Pfizer’s New Infant Pneumococcal Vaccine Trial: What Investors Should Watch
• Neutral Sentiment: Pfizer’s recent conference presentation and multiple earnings-related recap articles did not introduce a major new financial surprise, but they kept attention on post-earnings expectations and the company’s valuation. Pfizer Inc. (PFE) Presents at Jefferies Global Healthcare Conference 2026 Transcript
• Negative Sentiment: Some market commentary continues to highlight that PFE has been under pressure since its last earnings report, reflecting investor caution around near-term growth and execution. Why Is Pfizer (PFE) Down 4.5% Since Last Earnings Report?

Pfizer Trading Up 1.4%

NYSE:PFE opened at $26.04 on Friday. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67. The stock has a market capitalization of $148.43 billion, a price-to-earnings ratio of 19.88 and a beta of 0.34. The firm has a fifty day simple moving average of $26.62 and a two-hundred day simple moving average of $26.29. Pfizer Inc. has a 12 month low of $23.11 and a 12 month high of $28.75.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. The business had revenue of $14.45 billion during the quarter, compared to analysts’ expectations of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The business’s quarterly revenue was up 5.4% on a year-over-year basis. During the same period last year, the company posted $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Analysts expect that Pfizer Inc. will post 2.99 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 12th. Shareholders of record on Friday, May 8th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.6%. The ex-dividend date is Friday, May 8th. Pfizer’s dividend payout ratio (DPR) is presently 131.30%.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.